Pneumonia Testing Market

• Concerns about pneumonia mortality and increased pneumonia prevalence are driving the market growth

One of the main factors anticipated to drive the growth of the market CAGR is the notable increase in the prevalence of pneumonia worldwide. Pneumonia is generally more common in the elderly and pediatric populations. For instance, according to a 2019 United Nations International Children's Emergency Fund (UNICEF) article, there are more than 1,400 instances of pneumonia worldwide for every 100,000 people. Additionally, with 2,500 instances and 1,620 cases per 100,000 children, respectively, South Asia and West and Central Africa had the highest incidences of it. As a result, the aforementioned variables are significant market growth drivers.

Among all infectious diseases, pneumonia is regarded as one of the most frequent causes of hospitalization. If the patient is determined to be critically ill, additional microbiological testing for pneumonia is performed while the patient is hospitalized. For instance, according to estimates from the American Thoracic Society (ATS), each year, approximately 1.0 million adult Americans seek hospital care as a result of pneumonia. Guidelines for Community-Acquired Pneumonia (CAP) were released by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) since developed countries are also increasingly concerned about pneumonia testing.

It is anticipated that developing countries will follow these standards for pneumonia testing in order to raise awareness of the testing protocols. Therefore, the variables listed above are important catalysts for the expansion of the  market throughout the anticipated period.

Pneumonia testing market developments over time have included a change in consumer preferences and a rise in the demand for point-of-care diagnostics. Rapid diagnostic tools are desperately needed since pneumonia is becoming more common. The point-of-care testing segment is becoming popular among patients and healthcare professionals due to its main advantages, which include convenience, faster diagnosis times, and better treatment outcomes. As per a January 2020 NCBI post, quick syndromic molecular testing for pneumonia provide more accurate diagnosis than the present gold standard of culture.

The study indicated that commercially available syndromic diagnostic testing platforms, such as Unyvero and Filmarray Pneumonia panel, are more effective at detecting pneumonia than a traditional diagnostic technique.

The pneumonia testing market is growing thanks to the development of new, more precise, sensitive, and targeted testing techniques. Point-of-care (POC) testing is being used more often to identify pneumonia due to its increased efficacy and quick turnaround time for test results. The more sophisticated multiplex PCR (mPCR)-based pneumonia testing technology offers improved detection efficiency at a lower cost and in less time. Additionally, the use of antibiotics in the past had no effect on the DNA or RNA replication of minuscule microbes because it does not require live microorganisms.

Point-of-care testing is, therefore, being driven by the increased prevalence of chronic diseases among a broad consumer base that is adopting quick, affordable diagnostic testing. The POC test's ability to provide quick and precise results contributes to the advancement of patient-centered healthcare in bedside settings, which in turn encourages the use of point-of-care testing and, ultimately, the expansion of the pneumonia testing market. Thus, driving the pneumonia testing market revenue.

The Global Pneumonia Testing Market Industry is projected to experience substantial growth over the next decade. In 2024, the market is valued at 0.79 USD Billion, with expectations to reach 1.22 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 4.0% from 2025 to 2035. The increasing demand for pneumonia testing solutions, driven by factors such as rising incidence rates and technological advancements, is likely to contribute to this expansion. As the market evolves, stakeholders are expected to explore new opportunities and innovations to enhance testing capabilities.

Rising healthcare expenditure across various regions is a significant driver for the Global Pneumonia Testing Market Industry. As countries allocate more resources to healthcare, investments in diagnostic technologies are likely to increase. This trend is particularly evident in developing nations, where improving healthcare infrastructure is a priority. Enhanced funding allows for the procurement of advanced testing equipment and training for healthcare professionals. Consequently, the market is expected to experience a compound annual growth rate of 4.0% from 2025 to 2035. This growth reflects the ongoing commitment to improving pneumonia diagnosis and treatment.

The increasing incidence of pneumonia globally is a primary driver for the Global Pneumonia Testing Market Industry. According to health statistics, pneumonia remains a leading cause of morbidity and mortality, particularly among vulnerable populations such as children and the elderly. In 2024, the market is projected to reach 0.79 USD Billion, reflecting the urgent need for effective diagnostic solutions. Countries with high pneumonia rates are likely to invest in testing technologies to improve patient outcomes. This growing demand for accurate and rapid testing methods is expected to propel market growth significantly over the coming years.

Growing awareness of pneumonia and its impact on public health is driving the Global Pneumonia Testing Market Industry. Educational campaigns aimed at both healthcare professionals and the general public are increasing knowledge about pneumonia symptoms, risk factors, and the importance of early diagnosis. This heightened awareness is likely to lead to an increase in testing rates, as individuals seek medical attention sooner. As awareness continues to spread, the demand for pneumonia testing is expected to rise, potentially resulting in a market valuation of 1.22 USD Billion by 2035. This trend underscores the importance of education in improving health outcomes.

Government initiatives and funding play a crucial role in shaping the Global Pneumonia Testing Market Industry. Many countries are prioritizing pneumonia prevention and treatment through increased funding for healthcare programs. For instance, national health policies may include provisions for enhancing diagnostic capabilities and expanding access to testing. These initiatives are likely to foster collaboration between public and private sectors, leading to the development of new testing technologies. As governments recognize the economic burden of pneumonia, the allocation of resources towards testing solutions is expected to rise, contributing to market expansion.

Technological advancements in diagnostic tools are transforming the Global Pneumonia Testing Market Industry. Innovations such as molecular diagnostics, point-of-care testing, and artificial intelligence are enhancing the accuracy and speed of pneumonia detection. These advancements enable healthcare providers to make timely decisions, which is crucial for effective treatment. The integration of advanced technologies is likely to attract investments, further driving market growth. As the industry evolves, the adoption of these innovative solutions could lead to a more efficient healthcare system, ultimately improving patient care and reducing healthcare costs.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Pneumonia Testing market area will dominate this market. The increasing rate of pneumonia cases in the area served as a market driver for the market's expansion. The market is also growing as a consequence of the presence of major players in the field and the ongoing advancement of advanced PCR-based technologies that provide faster test results.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  PNEUMONIA TESTING MARKET SHARE BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Pneumonia Testing market accounts for the second-largest market share. During the forecast period, demand for pneumonia diagnostics products in Europe is expected to expand at a robust rate due to the rising prevalence of chronic diseases and an aging population. Similarly, during the next ten years, the pneumonia diagnostics market will likely benefit from the growing medical tourism industry as well as technological developments in diagnostics. Further, the German Pneumonia Testing market held the largest market share, and the UK Pneumonia Testing market was the fastest growing market in the European region.

The Asia-Pacific Pneumonia Testing Market is expected to grow at the fastest CAGR from 2025 to 2034. Since the elderly population is more prone to pneumonia, the growing geriatric population in Asia Pacific is significantly increasing the prevalence of pneumonia. Additionally, hospitalization rates are higher among the elderly, which has a substantial effect on morbidity and death. Moreover, China’s Pneumonia Testing market held the largest market share, and the Indian Pneumonia Testing market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Pneumonia Testing market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Pneumonia Testing industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Pneumonia Testing industry to benefit clients and increase the market sector. In recent years, the Pneumonia Testing industry has offered some of the most significant advantages to medicine. Major players in the Pneumonia Testing market are attempting to increase market demand by investing in research and development operations, including Bio-Rad Laboratories, Inc., Abbott, BioMérieux SA, Meridian Bioscience, Hologic Inc., Becton, Dickinson and Company, Curetis, Thermo Fisher Scientific, and Quidel Corporation.

Hologic Inc. is a company that develops, produces, and distributes surgical supplies, diagnostic tools, and medical imaging equipment. Along with GYN surgical products like hysteroscopic tissue removal systems and endometrial ablation systems, it also provides skeletal health products like dual-energy X-ray bone densitometry systems and mini C-arm imaging, as well as products that support human disease diagnosis and accessories and products related to breast imaging. The company supplies its goods to a variety of clientele, including hospitals, clinics, surgeons, and other medical professionals.

Development, production, and distribution of diagnostic test kits for viral, gastrointestinal, respiratory, and parasitic infectious disease indications are all done by the fully integrated life science company Meridian Bioscience Inc. (Meridian). In addition, the business produces bulk antigens, antibodies, nucleotides, purified reagents, and associated goods for use in manufacturing diagnostics and conducting research. It creates proteins and other biological materials for use in medicines and vaccine development biotechnology research.